New funding to take Vital's liver failure cell therapy through Phase III
This article was originally published in Scrip
Executive Summary
Vital Therapies closed the first $16 million from a $76 million funding commitment from its existing private investors to finance three pivotal Phase III clinical trials for the company's human allogeneic cellular therapy developed to treat acute liver failure.
You may also be interested in...
Eight Pivotal Trial Read-Outs Expected In Q3
A number of pivotal studies are expected to report top-line data in the third quarter. Here, with the help of Informa Pharma's Biomedtracker, we take a look at eight of those likely to be major catalysts for their sponsors.
Myovant Spurns Sumitovant Offer, Remains Open To Higher-Value Deal
Sumitovant offered $22.75 per share in cash, valuing Myovant at $2.4bn total, to acquire what it does not hold as a result of its 2019 agreement to buy majority shares of five Roivant companies.
Round Two: BioMarin Resubmits Hemophilia A Gene Therapy Roctavian In US
BioMarin maintains its lead in the race to win approval for a hemophilia A gene therapy in the US by resubmitting Roctavian two years after the FDA issued a CRL in response to the original BLA.